Centre Hospitalier de Macon

The medical center is at the forefront of research in rheumatology, with a particular focus on Giant Cell Arteritis. This condition, characterized by inflammation of the blood vessels, is being studied to improve patient outcomes through innovative treatment strategies.

• Giant Cell Arteritis
• Inflammatory Vascular Diseases
• Autoimmune Disease Management

By exploring the efficacy of different discontinuation protocols for medications like tocilizumab, the center aims to enhance relapse-free survival rates and optimize therapeutic approaches.

Specializing in hematology, the center conducts pioneering research on autoimmune hemolytic anemia and its complications. The focus is on preventing venous thromboembolic events through advanced anticoagulation therapies.

• Autoimmune Hemolytic Anemia
• Venous Thromboembolism Prevention
• Anticoagulation Therapy

Through studies on prolonged anticoagulation, the center seeks to establish effective prophylactic measures, thereby reducing the risk of thromboembolic complications in vulnerable patient populations.

The center is a leader in endocrinology, with a particular emphasis on managing complex conditions like "double diabetes". This involves patients with type 1 diabetes who also exhibit type 2 diabetes characteristics.

• Double Diabetes
• Glycemic Control
• GLP1 Agonist Therapy

Research on the use of GLP1 agonists, such as semaglutide, aims to improve glycemic control and enhance the quality of life for patients by optimizing time spent within target glucose levels.